MXPA03003407A - Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17. - Google Patents

Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.

Info

Publication number
MXPA03003407A
MXPA03003407A MXPA03003407A MXPA03003407A MXPA03003407A MX PA03003407 A MXPA03003407 A MX PA03003407A MX PA03003407 A MXPA03003407 A MX PA03003407A MX PA03003407 A MXPA03003407 A MX PA03003407A MX PA03003407 A MXPA03003407 A MX PA03003407A
Authority
MX
Mexico
Prior art keywords
rheumatoid arthritis
antagonists
methods
treating rheumatoid
treating
Prior art date
Application number
MXPA03003407A
Other languages
English (en)
Inventor
Kendall M Mohler
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of MXPA03003407A publication Critical patent/MXPA03003407A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Se describe un metodo para el tratamiento de un mamifero afectado con artritis reumatoide que comprende la administracion de una forma soluble de receptor IL-17.
MXPA03003407A 2000-10-18 2001-10-18 Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17. MXPA03003407A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24123000P 2000-10-18 2000-10-18
PCT/US2001/049504 WO2002058717A2 (en) 2000-10-18 2001-10-18 Methods for treating rheumatoid arthritis using il-17 antagonists

Publications (1)

Publication Number Publication Date
MXPA03003407A true MXPA03003407A (es) 2004-05-04

Family

ID=22909803

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003407A MXPA03003407A (es) 2000-10-18 2001-10-18 Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.

Country Status (7)

Country Link
US (5) US6793919B2 (es)
EP (1) EP1326626B1 (es)
JP (2) JP2004517918A (es)
AU (2) AU2002246746B2 (es)
CA (1) CA2425506A1 (es)
MX (1) MXPA03003407A (es)
WO (1) WO2002058717A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4373495B2 (ja) * 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US20040136992A1 (en) * 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
EP1641822B1 (en) 2003-07-08 2013-05-15 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
BRPI0608210A2 (pt) 2005-02-14 2010-11-09 Wyeth Corp métodos de diagnóstico de um distúrbio relacionado com il-17f em um indivìduo e de seleção de compostos capazes de inibirem a ligação de il-17f em il-17r, uso de um antagonista de il-17f, composição farmacêutica, e, adjuvante de vacina
AU2006214473A1 (en) * 2005-02-14 2006-08-24 Wyeth Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
AU2006294511B2 (en) * 2005-09-28 2011-11-17 Zymogenetics, Inc IL-17A and IL-17F antagonists and methods of using the same
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
CA2638864A1 (en) * 2006-02-10 2007-10-18 Zymogenetics, Inc. Truncated il-17ra soluble receptor and methods of using in inflammation
WO2008039553A1 (en) * 2006-02-10 2008-04-03 Zymogenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
ATE481089T1 (de) * 2006-05-31 2010-10-15 Vertex Pharma Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting- enzyme inhibitors
AU2007261019A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating IL-22 and IL-17
US7833527B2 (en) * 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
FR2908999B1 (fr) * 2006-11-29 2012-04-27 Biomerieux Sa Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide.
CL2008000883A1 (es) * 2007-03-28 2008-10-03 Wyeth6 3 Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
WO2008144610A1 (en) * 2007-05-18 2008-11-27 Medimmune, Llc Il-33 in inflammatory disease
EP2170958A1 (en) * 2007-06-13 2010-04-07 Amgen Inc. Il-17 heteromeric receptor complex
US20110195509A1 (en) * 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
US20100331545A1 (en) 2007-10-24 2010-12-30 Nippon Chemiphar Co., Ltd. Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient
BRPI0907196B1 (pt) * 2008-02-21 2021-05-25 Kirin-Amgen Inc Uso de um antagonista de il-17ra-il-17rb
WO2009147362A1 (en) * 2008-06-03 2009-12-10 Imperial Innovations Limited Method of rheumatoid arthritis treatment
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
AU2010303166A1 (en) * 2009-10-10 2012-05-24 Eleven Biotherapeutics, Inc. IL-17 family cytokine compositions and uses
MY182680A (en) 2010-01-15 2021-01-29 Amgen K A Inc Antibody formulation and therapeutic regimens
AR083546A1 (es) * 2010-10-25 2013-03-06 Genentech Inc Tratamiento de inflamacion gastrointestinal, soriasis y asma
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
US9133244B2 (en) 2011-01-18 2015-09-15 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
WO2013116682A1 (en) 2012-02-02 2013-08-08 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
CN108350032A (zh) 2015-10-09 2018-07-31 比奥尼斯有限责任公司 调节γC-细胞因子活性
US11866700B2 (en) 2016-05-06 2024-01-09 Exicure Operating Company Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
US20220144916A1 (en) * 2019-02-12 2022-05-12 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4354282A (en) * 1981-03-12 1982-10-19 Joseph F. Monahan, Jr. Garment with score indicia and attachable score recording markers
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
JP4373495B2 (ja) * 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
US6680057B1 (en) * 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
WO1997004097A2 (en) * 1995-07-19 1997-02-06 Genetics Institute, Inc. Human ctla-8 and uses of ctla-8-related proteins
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6080557A (en) * 1996-06-10 2000-06-27 Immunex Corporation IL-1/TNF-α-activated kinase (ITAK), and methods of making and using the same
US7005412B1 (en) * 1996-11-27 2006-02-28 Immunex Corporation Method of treating ulcerative colitis and Crohn's disease using IL-17 receptor proteins
DE69739375D1 (de) * 1996-11-27 2009-06-04 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid-erzeugung
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6635443B1 (en) * 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6185745B1 (en) * 1998-04-28 2001-02-13 Fred Alger Clothing combination comprising a self-releasing bonding fastening means
JP3577586B2 (ja) 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
JP2000186046A (ja) * 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
DE19911902C1 (de) * 1999-03-17 2000-08-03 Daimler Chrysler Ag Verfahren und Vorrichtung zur variablen Einstellung der Bremskraft in einer hydraulischen Bremsanlage eines Kraftfahrzeugs
EP1171148A2 (en) * 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AR028256A1 (es) 2000-03-16 2003-04-30 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
AR030554A1 (es) 2000-03-16 2003-08-27 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
US6497870B1 (en) * 2000-05-22 2002-12-24 Hyseq, Inc. Therapeutic uses of il-1 receptor antagonist
US7833527B2 (en) * 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies

Also Published As

Publication number Publication date
US6793919B2 (en) 2004-09-21
JP2004517918A (ja) 2004-06-17
AU2007205808A1 (en) 2007-09-06
WO2002058717A3 (en) 2003-02-27
US20050013814A1 (en) 2005-01-20
EP1326626A2 (en) 2003-07-16
AU2007205808B2 (en) 2009-10-15
US20020136724A1 (en) 2002-09-26
WO2002058717A2 (en) 2002-08-01
EP1326626B1 (en) 2020-04-01
US20100278840A1 (en) 2010-11-04
US20090130122A1 (en) 2009-05-21
CA2425506A1 (en) 2002-08-01
AU2007205808B8 (en) 2009-11-12
JP2009035554A (ja) 2009-02-19
US20090274703A1 (en) 2009-11-05
AU2002246746B2 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
MXPA03003407A (es) Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.
HUP0303766A3 (en) Ep4 receptor inhibitors to treat rheumatoid arthritis
MY141651A (en) Nep inhibitors for the treatment of female sexual dysfunction
HK1064921A1 (en) Sustained release formulations of oxymorphone
IL206829A0 (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
GB2375860B (en) Method and system for generating a set of search terms
HUS1000008I1 (hu) Oldható CTLA4 molekulák alkalmazása reumatoid artritisz kezelésére
PL327146A1 (en) Antagonists of the gonadotrophin liberating hormone
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
EP1255765A4 (en) PHARMACEUTICAL COMPOSITION AND THERAPEUTIC TREATMENT OF RHEUMATIC ARTHRITIS
GB0314858D0 (en) Apparatus and method for producing ash
HK1044029A1 (en) Method of producing an active mineral liquid from granite
AU2001225664A1 (en) 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
IL154419A0 (en) The treatment of inflammatory disorders
YU60803A (sh) Upotreba antagonista gal3 receptora u lečenju depresije i/ili uznemirenosti i jedinjenja korisna u tim postupcima
GB0124272D0 (en) Method of delivering money
DK0831835T3 (da) Behandling af anorexia
SE9904260D0 (sv) Method and device for producing beverages
UA49490A (uk) Спосіб лікування ревматоїдного артриту
GB0027896D0 (en) Process for strengthening of an underground formation
MXPA02010115A (es) Composiciones mejoradas para el tratamiento de la disfuncion erectil masculina.
SE0101257D0 (sv) Treatment of whiplash associated disorder
IL123536A0 (en) 5-HT3 Receptor antagonists for dyskinesia
UA49675A (uk) Спосіб лікування орнітозної пневмонії
UA33944A (uk) Спосіб інтраопераційної рн-метрії

Legal Events

Date Code Title Description
FG Grant or registration